Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari Sells 17,300 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 17,300 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $28.28, for a total value of $489,244.00. Following the transaction, the chief operating officer now owns 61,563 shares in the company, valued at $1,741,001.64. This trade represents a 21.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Eben Tessari also recently made the following trade(s):

• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total value of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.38, for a total value of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.46, for a total value of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $26.41, for a total value of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $20.48, for a total value of $245,760.00.

Kiniksa Pharmaceuticals International Trading Up 1.8%

KNSA stock traded up $0.51 during midday trading on Friday, hitting $28.44. The company's stock had a trading volume of 654,925 shares, compared to its average volume of 516,264. The company has a market cap of $2.08 billion, a PE ratio of -113.76 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.38 and a 12 month high of $30.69. The firm's 50-day moving average is $25.99 and its 200-day moving average is $22.39.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The firm's quarterly revenue was up 72.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.25) EPS. Analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Citigroup assumed coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Finally, Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $38.80.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC lifted its position in Kiniksa Pharmaceuticals International by 54.4% in the 1st quarter. Voya Investment Management LLC now owns 30,866 shares of the company's stock valued at $686,000 after acquiring an additional 10,878 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Kiniksa Pharmaceuticals International by 6.4% in the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock worth $1,393,000 after buying an additional 3,745 shares during the last quarter. Strs Ohio purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth $595,000. Acadian Asset Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 170.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after buying an additional 651,700 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth $485,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.